1. Introduction {#Section1}
===============

Breast cancer (BC) has become the most common cancer in women globally, accounting for nearly 2.1 million newly diagnosed cases in 2018 based on the data from Globocan [@B1]. Previous researches have evidenced that early diagnosis and timely treatment of BC would exert a significant effect on improving the prognosis of BC patients [@B2]. As the most widely used tumor markers for BC, neither CA 15-3 nor CEA have satisfactory sensitivities and specificities for early diagnosis [@B3]. Although annual digital mammography (DM) has been regarded as an effective way to reduce the mortality of BC in age-appropriate asymptomatic women, the sensitivity tends to depend on tissue density and tumor growth patterns [@B4]. Recent studies indicated that the digital breast tomosynthesis (DBT) might have the potential to replace DM in the early detection of BC, with a preponderance of sensitivity in dense breast to some extent, but an overview of these small-scale evidences came to a conclusion that it is still insufficient to confirm a shift from DBT to DM [@B5]. Therefore, novel effective and convenient methods for early diagnosis of BC are urgently needed.

Metabolomics is an emerging powerful technique measuring endogenous metabolic substances in response to internal and external changes of the whole body [@B6] (Figure [1](#F1){ref-type="fig"}). The molecules produced by cancer cells during their growth could enter into the urine, blood or tissue, which underlies the potential to discover valuable biomarkers for early diagnosis [@B7]. In recent years, the technique of metabolomics has been widely used in the discovery of biomarkers in various cancers and served as an effective approach for personalized medicine.

In this study, we performed a systematic review about the clinical and cellular metabolomic researches in the diagnosis of BC over the past decade, pursuing an overall perspective over the potential application of metabolomics in the diagnosis of BC and discovery of reliable metabolic biomarkers and pathways for BC.

2. Materials and Methods {#Section2}
========================

2.1 Literature Searching {#Section2.1}
------------------------

Researchers conducted an advanced retrieval on the PMC platform with the following searching strings: ("metabolomics" OR "metabolic profiling" OR "metabolic profiles" OR "metabolic biomarkers" OR "metabolome" OR "metabolic protraits") AND ("breast" OR "mammary") AND ("tumor" OR "tumour" OR "cancer" OR "carcinoma" OR "neoplasm"). Literatures published between 2008/01/01 and 2019/08/01 were included in the index, with a result of 12068 records. Two researchers searched the articles independently and the third one made the final decision if necessary.

2.2 Inclusion and Exclusion Criteria {#Section2.2}
------------------------------------

To lower the missing rate of targeted records, relevant metabolomic studies were all included except the following: 1) purposes beyond the diagnosis of BC; 2) review articles; 3) metabolites detected without metabolomics methodology; 4) animal models; 5) deficiency of concrete metabolites or their level variations. Eventually, 50 items including 38 clinical researches, 11 cellular researches and 1 clinical and cellular research were remained with required information recorded (Figure [2](#F2){ref-type="fig"}).

2.3 Data Extraction {#Section2.3}
-------------------

Information from selected literatures was extracted as followed.

1\) Title, first author and publication year;

2\) Purpose, study subjects (case and control) and analytical techniques;

3\) The significant metabolites with changing trends.

2.4 Statistical Analysis {#Section2.4}
------------------------

Frequencies on detecting instruments, biological specimens, sample sizes, study designs and repeatedly reported biomarkers were counted and graphed. The pathway analysis of metabolite markers in BC, including enrichment analysis and pathway topology analysis, was performed using the online software of *Metaboanalyst* (<http://www.metaboanalyst.ca/>).

3. Results {#Section3}
==========

3.1 Clinical Researches {#Section3.1}
-----------------------

### 3.1.1 Study Characteristics {#Section3.1.1}

A total of 39 articles[@B8]-[@B46] were included in the final analysis (Supplementary [Table S1](#SM0){ref-type="supplementary-material"}), among which 22 studies were performed with blood (serum or plasma), 8 with urine, 5 with tissue, 5 with saliva and 1 with ductal fluid (Figure [3](#F3){ref-type="fig"}A). Mass-spectrometry based metabolomics studies reached 35 articles, while NMR was adopted in 6 studies (Figure [3](#F3){ref-type="fig"}B). Eighteen studies were targeted, and the other 22 studies were untargeted (Figure [3](#F3){ref-type="fig"}C). Study sample sizes summing the case and control varied from 3 to 1172, with only 2 studies bigger than 500 (Figure [3](#F3){ref-type="fig"}D).

### 3.1.2 Analysis of High Frequency Metabolic Biomarkers {#Section3.1.2}

In all, 492 metabolite markers mentioned in these diagnosis-related studies were recorded. Table [1](#T1){ref-type="table"} summarized 33 metabolic biomarkers with high frequency (reported in ≥ 3 studies). Tyrosine has the highest frequency with 12 hits in total, followed by alanine reported with 11 hits. In studies focusing on the tissue [@B16], [@B18], [@B36], [@B37], [@B40], most significant metabolites tended to be up-regulated except glucose. Notably, changes of some fatty acids like palmitic acid, linoleic acid and stearic acid were consistently increased in the blood.

### 3.1.3 Analysis of Metabolic Pathways {#Section3.1.3}

A total of 492 significant metabolites were imported to *MetaboAnalyst* for the identification of involved metabolic pathways (Figure [4](#F4){ref-type="fig"}). Those significantly enriched pathways (raw *P*\<0.005) included arginine and proline metabolism, glycine, serine and threonine metabolism, aminoacyl-tRNA biosynthesis, alanine, aspartate and glutamate metabolism, glutathione metabolism and so on (Table [2](#T2){ref-type="table"}). Particularly, two pathways (alanine, aspartate and glutamate metabolism and arginine and proline metabolism**)** performed an impact of 0.85945 and 0.70435, respectively.

### 3.1.4 Diagnostic potential of metabolite markers for discriminating BC {#Section3.1.4}

Twenty-two of these studies comparing BC patients with controls reported exact AUC values ranging from 0.627 to 1.000 (Table [3](#T3){ref-type="table"}). In addition, Mónica Cala et al. [@B22] demonstrated that specific built-up biomarkers like dimethylheptanoylcarnitine and succinic acid could have a higher sensitivity and specificity (93.5%, 86.2%) than either dimethylheptanoylcarnitine (71.0%, 75.9%) or succinic acid (67.7%, 75.9%). Notably, the stage of BC patients has a certain influence on the results according to three selected studies [@B13], [@B30], [@B41].

3.2 Cellular Researches {#Section3.2}
-----------------------

### 3.2.1 Study Characteristics {#Section3.2.1}

Cellular researches were relatively fewer than clinical researches, and 12 cellular studies [@B32], [@B47]-[@B57] were ultimately included (Supplementary [Table S2](#SM0){ref-type="supplementary-material"}). MCF-10A, mentioned in 8 articles, led the most common normal cell line being studied. As for BC cell lines, MDA-MB-231 was adopted most frequently in 8 studies, followed by MCF-7 in 7 studies and both MDA-MB-453 and BT-474 in 3 studies (Figure [5](#F5){ref-type="fig"}A). Only one study detected metabolites using a NMR-related methodology, and the other 11 studies all adopted mass-spectrometry based metabolomics (Figure [5](#F5){ref-type="fig"}B). Targeted and untargeted metabolomics both accounted for 6 articles (Figure [5](#F5){ref-type="fig"}C).

### 3.2.2 Analysis of High Frequency Metabolic Biomarkers {#Section3.2.2}

There were 84 significant metabolites in the BC cells compared with normal breast epithelial cells. Differential metabolites reported in two studies included decreased amino acids (e.g. leucine, isoleucine, valine, phenylalanine [@B47], [@B51] and glutamine [@B47], [@B57]), increased lipids (e.g. phosphocholine [@B53], [@B56]) and RNA metabolites (e.g. 3-methylcytidine and 5-methyluridine [@B49], [@B52]). Moreover, decreased glucose was observed in two studies [@B53], [@B57] (Table [4](#T4){ref-type="table"}).

### 3.2.3 Analysis of Metabolic Pathways {#Section3.2.3}

A total of 84 metabolites were imported to *MetaboAnalyst* for the identification of involved metabolic pathways (Figure [6](#F6){ref-type="fig"}). Finally, significantly enriched metabolic pathways (raw *P*\<0.005) included aminoacyl-tRNA biosynthesis, glycerophospholipid metabolism, glycolysis or gluconeogenesis, alanine, aspartate and glutamate metabolism, glycine, serine and threonine metabolism and so on (Table [5](#T5){ref-type="table"}). Notably, alanine, aspartate and glutamate metabolism had the highest impact value (impact= 0.51757).

4. Discussion {#Section4}
=============

In this study, we performed a systematic analysis of clinical and cellular metabolomic studies on BC diagnosis. As a result, a series of potential biomarkers were reported and summarized. A total of 33 high-frequency metabolites in clinical researches (reported in ≥3 studies) were listed, and some metabolic biomarkers (e.g. palmitic acid, linoleic acid, stearic acid and lipids.) showed consistent changing trends. In addition, pathway analysis revealed several important metabolic pathways for BC, particularly alanine, aspartate and glutamate metabolism with the highest impact, both in cellular and clinical studies.

When comparing clinical and cellular researches, we found that some significant metabolites (e.g. leucine, isoleucine, valine, phenylalanine, glutamine and glucose) were repeatedly reported in both types of studies. Moreover, five metabolic pathways were significantly enriched in both types of studies (FDR\<0.05), including glycine, serine and threonine metabolism, aminoacyl-tRNA biosynthesis, alanine, aspartate and glutamate metabolism, nitrogen metabolism and glycerophospholipid metabolism. Along with the heterogeneity of BC, metabolites in different patients could vary based on different samples, tumor characteristics and dietary structures [@B58]. By contrast, cellular studies have an advantage of avoiding the heterogeneity resulting from diverse samples. However, metabolites detected could also be fluctuant, which is induced by the incubation time [@B47], [@B51] and PH of mediums [@B48].

Screening mammography has been acknowledged as the gold standard for early detection of BC, with sensitivities of 54%\~77% [@B59]. Despite the rapid development of many imaging techniques, their utilizations are limited to the high cost and insufficient sensitivities and specificities [@B60]. Due to the important role of immune system in the process of tumors\' origin and development, tumor antigen-specific autoantibodies can be potentially applied to cancer detection as early biomarkers. However, currently used tumor markers usually have low diagnostic specificities and sensitivities as well [@B61]. Vathany\'s study suggested that cancer biomarkers could be measured in serum by immunological techniques with superiorities of convenience, relative non-invasion and being tested independently by operators [@B61]. As evidenced by the preponderant sensitivities and specificities in previous studies, metabolomics has shown advantages in the early diagnosis of BC. It is well known that an acceleration of glyconeogenesis, glycolysis and fat mobilization, and a decrease in protein synthesis, are the main metabolic changes in malignant tumors. The following discussion will expand from three basic metabolic pathways to discover their sensitivities and specificities for BC (Figure [7](#F7){ref-type="fig"}).

4.1 Energy Metabolism {#Section4.1}
---------------------

Altered utilization of energy relative to normal cells caused by the proliferative tumor cells is an acknowledged hallmark of several cancers [@B62]. In glycolysis metabolism, a decreasing trend of glucose [@B23], [@B34], [@B37], [@B53], [@B57] and an increasing tendency of lactate [@B11], [@B17], [@B21], [@B37], [@B57] were observed in BC. This phenomenon might be accounted for a shift in energy production of tumor cells with a preference to anaerobic glycolysis even in the presence of oxygen, known as the Warburg effect [@B63], which is a better way for the rapid acquisition of energy and self-protection by immune disruptions with an acidic environment [@B64]. As a result of favoring the carbon source, MCF-7 cells were more likely to accomplish the complete oxidation of carbon consumption than 48R cells [@B57]. Moreover, higher lactate levels had been found associated with lower 5-year survival rates [@B65]. Notably, an increasing level of pyruvate can be bound up with an enhanced glycolytic activity [@B43], [@B66]. A high level of anaerobic glycolysis could reduce intermediates in the TCA cycle, resulting in a suppressed TCA cycle [@B43], which might be one of the reasons for down-regulations of branched chain amino acids (BCAAs) in the tissue of BC including leucine, isoleucine and valine [@B67].

4.2 Amino Acid Metabolism {#Section4.2}
-------------------------

Former studies suggested that several decreased amino acids might be the result of excessive consumption or preferential utilization to sustain the uncontrolled growth of BC cells [@B18], [@B22], [@B24], [@B27], [@B42], [@B47], [@B51], [@B68]. Based on clinical metabolomic studies, tyrosine and alanine shared the highest frequency with 12 hits, indicating they might be sensitive metabolites in the diagnosis of BC. Although the changing trend of tyrosine among different studies were inconsistent, previous research has demonstrated that tyrosine deficiency could result in BC cell growth arrest [@B69], and inhibition of tumor growth has been confirmed in low phenylalanine and tyrosine diets in an animal study [@B70]. Recent studies also showed that alanine had a significant difference between estrogen receptor positive and estrogen receptor negative breast cancer [@B71]-[@B72]. In addition, alanine and valine could result in cell damage by decreasing the activity of manganese superoxide dismutase (MnSOD), thereby converting benign tumor to malignant tumor [@B73].

Pathway analysis showed that alanine, aspartate and glutamate metabolism played an important role in the development of BC. The down-regulated glutamine indicated that glutamic acid might be accumulated in the body, which promotes the occurrence of BC by enhancing the proliferation of mammary epithelial cells [@B73] through ATP production and biosynthesis of nucleotides [@B74]. Moreover, the up-regulated glutamic acid via glutaminolysis could maintain the TCA cycle [@B75]. Researchers also observed that the reversibility of glutamine-glutamate was decreasing in MCF-7 cells, implying that BC cells might be partial to the irreversible glutaminase [@B57]. The change of glutamine could be reflected in the fluctuant levels of alanine and aspartic acid through the abnormal transport of ammonia. Higher activities of histidine decarboxylase might result in decreasing histidine since decarboxylation of histidine by this enzyme in the colorectal cancer has been reported [@B76]-[@B77]. Therefore, the low concentrations of histidine could be accounted for increased aspartic acid and glutamic acid, which could be converted to oxaloacetic acid and α-ketoglutaric acid, the intermediates of TCA cycle. Aspartic acid has been shown to possess a higher sensitivity for BC compared with gastric and colorectal cancer [@B32]. Therefore, increasing utilization of aspartic acid by BC cells might result in down-regulated aspartic acid and oxaloacetate in the blood. Notably, as a transamination product of aspartic acid, asparagine has a vital influence on the metastasis of BC [@B78]. Furthermore, with the role of modifying the indices of oxidative stress and membrane damage, increased hypotaurine could be potentially linked with BC [@B79].

4.3 Lipid Metabolism {#Section4.3}
--------------------

Previous studies had put large efforts to figure out the importance of lipid metabolism in the diagnosis of breast cancer [@B21], [@B26], [@B31], [@B35], [@B38]-[@B40], [@B50], [@B54], [@B56], but deterministic conclusions are still on the road due to the complexity. It is well known that an increase of choline in the tissue could be a hallmark of aggressiveness breast cancer [@B80], therefore, excessive consumption of choline could result in its lower blood levels [@B23], [@B30], [@B32], [@B34]. The phenomenon that phospholipid metabolism shares the trend of upregulation integrally [@B21], [@B23] could be explained by an enhanced fatty acid (FFA) oxidation to confer limitless growth or survival advantage[@B81], mainly through inducing more exalted cell membrane turnover and lipid activity in intracellular signal transduction [@B82]-[@B84]. Remarkably, increased phosphocholine has been reported in other cancers, such as lung cancer [@B85], prostate cancer [@B86], brain cancer [@B87], colorectal cancer [@B88] and cervical cancer [@B89]. Fatty acid synthase (FANS) has also been confirmed to be highly expressed in the MCF-7 cells and tissue of BC patients [@B90]. Linoleic acid, stearic acid and palmitic acid were consistently detected in different studies with elevated levels in BC. Linoleic acid could promote BC via modulating Breast Cancer Susceptibility Gene 1 (BRCA1) [@B91]. Meanwhile, linoleic acid could increase the production of 20-hydroxyeicosatetraenoic acid (12-HETE), 15-hydroxyeicosatetraenoic acid (15-HETE) and prostaglandin E2 [@B92], which helps increase the modulation of adhesion and the membrane fluidity to promote BC [@B93]. Palmitic acid and stearic acid, as two common saturated fatty acids, were confirmed to inhibit insulin metabolism and attenuate insulin signal transduction [@B94]. Furthermore, a previous study demonstrated that a high level of palmitic acid in erythrocyte could increase the risk of BC [@B95]. Acetone, one of ketone bodies, was also suggested to be an aggressive biomarker of BC cells [@B53]. As another important way to provide energy in lipid metabolism, ketone bodies that are promoted by glycolytic stromal cells might provoke tumor growth and metastasis by accelerating oxidative mitochondrial metabolism [@B96].

5. Conclusions {#Section5}
==============

In conclusion, numerous available publications have demonstrated the potential of metabolic profiling applied to the diagnosis of BC. Our review presents that there indeed exist certain metabolisms in BC patients, which could lay foundation for biomarker discovery for BC diagnosis and shed new light into the development and progression of BC. Moreover, with the advantages of convenience and relative non-invasion compared with imaging screening and tissue biopsy, metabolomics may be considered as an applicable tool in the diagnosis of early BC.
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###### 

High frequency clinical metabolic biomarkers related to BC diagnosis

  No.   Metabolites             Hits   Changing Direction in BC                                                       
  ----- ----------------------- ------ ------------------------------------------------------------------------------ ---------------------------------------------------------------------
  1     Tyrosine                12     6 serum[@B15], [@B27], plasma[@B17], tissue[@B18], saliva[@B42], urine[@B46]   6 plasma[@B9], [@B34], [@B41], serum[@B14], [@B18], [@B23]
  2     Alanine                 11     6 saliva[@B11], [@B42], serum[@B15], plasma[@B21], [@B41], urine[@B43]         5 plasma[@B9], [@B34], serum[@B14], urine[@B22], serum&plasma[@B30]
  3     Glutamic acid           10     6 serum[@B15], tissue[@B16],[@B18], plasma[@B21], saliva[@B17],[@B42]          4 plasma[@B9], serum[@B14], urine[@B22], serum&plasma[@B32]
  4     Valine                  10     4 saliva[@B11], [@B42], serum[@B15], plasma[@B21]                              6 plasma[@B9], [@B17], [@B24], [@B34], serum[@B14], urine[@B22]
  5     Phenylalanine           9      5 serum[@B15], tissue[@B18], saliva[@B26], [@B42], urine[@B46]                 4 plasma[@B9], [@B34], [@B41], serum[@B18]
  6     Glutamine               9      4 saliva[@B11], serum[@B15],tissue[@B18], serum&plasma[@B32]                   5 plasma[@B12], [@B17], [@B24], [@B41] serum[@B14]
  7     Lysine                  9      3 plasma[@B17], [@B41], saliva[@B42]                                           6 plasma[@B9], [@B12], [@B24], serum[@B14], [@B23], [@B27]
  8     Isoleucine              8      4 saliva[@B11], serum[@B15], plasma[@B21], urine[@B43]                         4 serum[@B14], plasma[@B17], [@B34], serum&plasma[@B32]
  9     Histidine               7      3 serum[@B15], tissue[@B18], saliva[@B26]                                      4 serum[@B14], [@B23], [@B27], plasma[@B41]
  10    Choline                 7      3 saliva[@B11], plasma[@B12], tissue[@B36]                                     4 serum[@B23], serum&plasma[@B30], [@B32], plasma[@B34]
  11    Glycine                 6      4 serum[@B15], tissue[@B37], plasma[@B41] , saliva[@B42]                       2 urine[@B22], serum&plasma[@B30]
  12    Arginine                6      3 serum[@B10], saliva[@B11], plasma[@B17]                                      3 serum[@B14], [@B15], plasma[@B24]
  13    Asparagine              6      4 plasma[@B13], serum[@B15], serum&plasma[@B32], urine[@B43]                   2 plasma[@B9], serum[@B27]
  14    Proline                 6      3 serum[@B15], plasma[@B41], saliva[@B42]                                      3 plasma[@B13], serum[@B14], [@B27]
  15    Serine                  6      5 saliva[@B11], [@B42], serum[@B15], plasma[@B21], [@B41]                      1 serum&plasma[@B30]
  16    Creatine                6      3 tissue[@B18], [@B37], urine[@B43]                                            3 serum[@B18], plasma[@B24], [@B34]
  17    Leucine                 6      2 saliva[@B11], urine[@B43]                                                    4 plasma[@B9], [@B34], serum[@B14], urine[@B22]
  18    Tryptophan              6      1 serum[@B33]                                                                  5 serum[@B14], [@B18], [@B27], urine[@B22], plasma[@B41]
  19    Lactate                 6      4 saliva[@B11], plasma[@B17], [@B21], tissue[@B37]                             2 serum&plasma[@B32], plasma[@B34]
  20    Threonine               5      2 plasma[@B41], saliva[@B42]                                                   3 plasma[@B9], serum[@B14], urine[@B22]
  21    Taurine                 5      4 plasma[@B13], [@B24], serum[@B15], tissue[@B37]                              1 saliva[@B42]
  22    Glucose                 5      2 plasma[@B17], urine[@B43]                                                    3 serum[@B23], plasma[@B34], tissue[@B37]
  23    Aspartic acid           4      3 serum[@B10], tissue[@B16], saliva[@B42]                                      1 serum&plasma[@B32]
  24    Stearic acid            4      4 plasma[@B13], [@B21], [@B24], serum[@B38]                                    
  25    Ornithine               4      2 plasma[@B41], saliva[@B42]                                                   2 plasma[@B9], serum[@B14]
  26    Cysteine                4      2 serum[@B15], serum&plasma[@B32]                                              2 urine[@B22], serum[@B27]
  27    Glycerophosphocholine   4      2 plasma[@B12], tissue[@B36]                                                   2 serum&plasma[@B32], saliva[@B42]
  28    Pyruvate                3      2 serum&plasma[@B30], plasma[@B34]                                             1 serum[@B18]
  29    Linoleic acid           3      3 plasma[@B21], [@B24], serum[@B38]                                            
  30    Palmitic acid           3      3 plasma[@B13], [@B21], serum[@B38]                                            
  31    Uracil                  3      2 serum&plamsa[@B32], urine[@B43]                                              1 urine[@B22]
  32    Urea                    3      2 urine[@B43], [@B45]                                                          1 plasma[@B8]
  33    Formate                 3      1 urine[@B43]                                                                  2 serum[@B10], plasma[@B17]

###### 

Significant metabolic pathways related to BC diagnosis in clinical researches

  Pathway Name                                  Raw *P*    Holm Adjust   FDR\*      Impact
  --------------------------------------------- ---------- ------------- ---------- ---------
  Arginine and proline metabolism               6.69E-09   5.35E-07      5.35E-07   0.70435
  Glycine, serine and threonine metabolism      4.27E-08   3.37E-06      1.71E-06   0.53424
  Aminoacyl-tRNA biosynthesis                   5.59E-07   4.36E-05      9.45E-06   0.22536
  Alanine, aspartate and glutamate metabolism   5.61E-07   4.36E-05      9.45E-06   0.85945
  Nitrogen metabolism                           5.91E-07   4.49E-05      9.45E-06   0.00830
  Glutathione metabolism                        1.80E-05   0.0013531     2.41E-04   0.34568
  beta-Alanine metabolism                       2.77E-05   0.0020517     3.17E-04   0.41674
  Glycerophospholipid metabolism                6.21E-04   0.0453150     0.006208   0.41257
  Cysteine and methionine metabolism            0.001042   0.0750390     0.009264   0.50502
  Glyoxylate and dicarboxylate metabolism       0.001342   0.0952670     0.010734   0.46883
  Citrate cycle (TCA cycle)                     0.003391   0.2373800     0.022608   0.42880
  Taurine and hypotaurine metabolism            0.003391   0.2373800     0.022608   0.46583
  Pantothenate and CoA biosynthesis             0.003890   0.2645400     0.023940   0.25300

\*FDR: false discovery rate

###### 

The potential for metabolite markers in the diagnosis of BC

  Ref.                                Sample         Sensitivity   Specificity                   AUC                           Potential Biomarker(s)                        Note
  ----------------------------------- -------------- ------------- ----------------------------- ----------------------------- --------------------------------------------- ---------------------------------------------------------
  Baowen Yuan [@B9](2019)             plasma         \-            \-                            0.870                         all significant metabolites                   BC vs HC(training)
  \-                                  \-             0.800         all significant metabolites   BC vs HC(validation)                                                        
  Paniz Jasbi [@B13](2019)            plasma         80.00%        75.00%                        0.890                         all significant metabolites                   BC vs HC
  \-                                  \-             0.760         proline                       BC vs HC                                                                    
  86.00%                              75.00%         0.870         all significant metabolites   EBC vs HC                                                                   
  Dan Tudor Eniu [@B14](2019)         serum          83.33%        76.92%                        0.850                         isoleucine                                    BC vs HC
  66.67%                              92.31%         0.850         tryptophan                    BC vs HC                                                                    
  Xinyang Wang [@B15](2018)           serum          \-            \-                            0.924                         glutamic acid                                 BC vs HC
  \-                                  \-             0.901         taurine                       BC vs HC                                                                    
  \-                                  \-             0.749         ethylmalonic acid             BC vs HC                                                                    
  Shankar Suman [@B17](2018)          plasma         \-            \-                            0.818                         β-glucose                                     BC vs HC
  \-                                  \-             0.780         α-glucose                     BC vs HC                                                                    
  \-                                  \-             0.780         lactate                       BC vs HC                                                                    
  \-                                  \-             0.697         hydroxybutyrate               BC vs HC                                                                    
  \-                                  \-             0.652         N-acetyl glycoprotein         BC vs HC                                                                    
  \-                                  \-             0.627         lysine                        BC vs HC                                                                    
  Tushar H. More [@B18](2018)         tissue         \-            \-                            0.970                         guanine                                       IDC vs HC
  \-                                  \-             0.830         tyrosine                      IDC vs BE                                                                   
  \-                                  \-             0.960         tyrosine                      IDC vs HC                                                                   
  serum                               \-             \-            0.980                         ascorbic acid                 IDC vs HC                                     
  \-                                  \-             0.830         uridine diphosphate           IDC vs BE                                                                   
  Mónica Cala [@B22](2018)            urine          93.50%        86.20%                        0.915                         dimethylheptanoylcarnitine +succinic acid     BC vs HC
  Mariona Jové [@B24](2017)           plasma         100.00%       100.00%                       1.000                         C26H43ClN4S3                                  BC vs HC
  100.00%                             100.00%        1.000         C26H51N5O4                    BC vs HC                                                                    
  100.00%                             100.00%        1.000         C9H16O3S                      BC vs HC                                                                    
  100.00%                             100.00%        0.999         C23H30N2S                     BC vs HC                                                                    
  100.00%                             100.00%        0.995         caproic acid                  BC vs HC                                                                    
  100.00%                             90.00%         0.952         taurine                       BC vs HC                                                                    
  90.00%                              90.00%         0.959         stearamide                    BC vs HC                                                                    
  100.00%                             90.00%         0.935         linoleic acid                 BC vs HC                                                                    
  Naila Irum Hadi [@B25](2017)        serum          96.00%        100.00%                       0.990                         all significant metabolites                   BC vs HC
  Liping Zhong [@B26](2016)           saliva         92.60%        91.70%                        0.929                         MG(0:0/14:0/0:0)                              BC vs HC
  77.80%                              100.00%        0.920         LysoPC (18:1)                 BC vs HC                                                                    
  81.50%                              91.70%         0.920         LysoPC (22:6)                 BC vs HC                                                                    
  Qingjun Wang [@B27](2016)           serum          90.30%        87.40%                        0.944                         all significant metabolites                   BC vs BE(HC)
  Takahiro Takayama [@B28](2016)      saliva         68.90%        74.40%                        0.744                         spermine.                                     BC vs HC
  Luisa Matos Do Canto [@B29](2016)   ductal fluid   90.70%        88.40%                        0.956                         all significant metabolites                   BC vs HC
  Sijia Huang [@B30](2016)            plasma         \-            \-                            0.986                         all significant metabolites                   BC vs HC(training)
  \-                                  \-             0.995         all significant metabolites   EBC vs HC(training)                                                         
  \-                                  \-             0.923         all significant metabolites   BC vs HC(testing)                                                           
  \-                                  \-             0.905         all significant metabolites   EBC vs HC(testing)                                                          
  serum                               \-             \-            0.995                         all significant metabolites   BC vs HC(validation)                          
  \-                                  \-             0.902         all significant metabolites   EBC vs HC(validation)                                                       
  Guoxiang Xie [@B32](2015)           plasma         100.00%       100.00%                       1.000                         aspartic acid                                 BC vs HC(training)
  100.00%                             94.30%         0.996         glycerolphosphate             BC vs HC(training)                                                          
  plasma                              85.40%         95.10%        0.935                         aspartic acid                 BC vs HC(validation)                          
  95.10%                              93.20%         0.971         glycerolphosphate             BC vs HC(validation)                                                        
  Yunping Qiu [@B35](2013)            plasma         98.10%        96.00%                        \-                            LysoPC a C16:0, PC ae C42:5 and PC aa C34:2   BC vs HC
  Tone F. Bathen [@B37](2013)         tissue         91.00%        93.00%                        \-                            all significant metabolites                   BC patientstumor tissue vs non-involved adjacent tissue
  Wuwen Lv [@B38](2012)               serum          82.80%        85.30%                        0.892                         C16:0                                         BC vs HC
  89.70%                              85.00%         0.925         C16:0                         BC vs BE                                                                    
  Yohei Miyagi [@B41](2011)           plasma         \-            \-                            0.778                         all significant metabolites                   BC vs HC
  \-                                  \-             0.813         all significant metabolites   Stage 0 BC vs HC                                                            
  \-                                  \-             0.754         all significant metabolites   Stage I BC vs HC                                                            
  \-                                  \-             0.786         all significant metabolites   Stage II BC vs HC                                                           
  \-                                  \-             0.755         all significant metabolites   Stage III BC vs HC                                                          
  Masahiro Sugimoto [@B42](2010)      saliva         \-            \-                            0.973                         all significant metabolites                   BC vs HC
  Carolyn M. Slupsky [@B43](2010)     urine          100.00%       93.00%                        \-                            all significant metabolites                   BC vs HC
  Hojung Nam [@B45](2009)             urine          \-            \-                            0.790                         all significant metabolites                   BC vs HC

###### 

High frequency cellular metabolic biomarkers related to BC diagnosis

  No.   Metabolites        Hits   Changing direction in BC   
  ----- ------------------ ------ -------------------------- -----------------
  1     Leucine            2                                 2[@B47], [@B51]
  2     Isoleucine         2                                 2[@B47], [@B51]
  3     Valine             2                                 2[@B47], [@B51]
  4     Phenylalanine      2                                 2[@B47], [@B51]
  5     Glutamine          2                                 2[@B47], [@B57]
  6     Glucose            2                                 2[@B53], [@B57]
  7     Phosphocholine     2      2[@B53], [@B56]            
  8     3-Methylcytidine   2      2[@B49], [@B52]            
  9     5-Methyluridine    2      2[@B49], [@B52]            

###### 

Significant metabolic pathways related to BC diagnosis in cellular researches

  Pathway Name                                  Raw *P*     Holm Adjust   FDR^\*^     Impact
  --------------------------------------------- ----------- ------------- ----------- ---------
  Aminoacyl-tRNA biosynthesis                   6.23E-08    0.00000       4.98E-06    0.11268
  Nitrogen metabolism                           9.91E-07    0.00008       3.97E-05    0.00830
  Glycerophospholipid metabolism                1.66E-05    0.00129       4.42E-04    0.32074
  Glycolysis or Gluconeogenesis                 7.21E-05    0.00555       0.0014422   0.14226
  Alanine, aspartate and glutamate metabolism   3.62E-04    0.02753       0.0057956   0.51757
  Valine, leucine and isoleucine biosynthesis   5.79E-04    0.04345       0.006910    0.06148
  Glycine, serine and threonine metabolism      6.05E-04    0.04474       0.006910    0.13604
  Cyanoamino acid metabolism                    0.0015061   0.10995       0.015061    0.00000

\*FDR: false discovery rate
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